Our results further support the idea that dietary supplementation using n-3 LC-PUFA could improve the efficacy of TZDs, as well as other insulin-sensitizing and hypolipidemic pharmaceuticals used for the treatment of obese and type 2 diabetic patients. Here, INS is linked to type 2 diabetes mellitus.